Results 31 to 40 of about 2,265 (188)

Novel Biological Therapies for Severe Asthma Endotypes [PDF]

, 2022
Severe asthma comprises several heterogeneous phenotypes, underpinned by complex pathomechanisms known as endotypes. The latter are driven by intercellular networks mediated by molecular components which can be targeted by specific monoclonal antibodies.
Calabrese C., Crimi C., Longhini F., Maglio A., Pelaia C., Pelaia G., Stanziola A. A., Terracciano R., Vatrella A.   +8 more
core   +2 more sources

Safety and efficacy of tezepelumab vs. placebo in adult patients with severe uncontrolled asthma: a systematic review and meta-analysis

Scientific Reports, 2022
Patients with severe uncontrolled asthma still experience acute asthma symptoms and exacerbations, particularly those with non-eosinophilic inflammation who take the maximum amount of standard drug therapy.
Mahmoud Shaban Abdelgalil, Asmaa Ahmed Elrashedy, Ahmed K. Awad, Eman Reda Gad, Mahmoud M. Ali, Ramadan Abdelmoez Farahat, Bassant Hassan Shawki, Mohamed Abd-ElGawad   +7 more
doaj   +1 more source

CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma

Respiratory Research, 2020
Background Patients with severe, uncontrolled asthma, particularly those with a non-eosinophilic phenotype, have a great unmet need for new treatments that act on a broad range of inflammatory pathways in the airway.
Claire Emson, Sarah Diver, Latifa Chachi, Ayman Megally, Cherrie Small, John Downie, Jane R. Parnes, Karin Bowen, Gene Colice, Chris E. Brightling   +9 more
doaj   +1 more source

Monoclonal antibodies in type 2 asthma : a systematic review and network meta-analysis [PDF]

, 2019
Since novel treatments to target eosinophilic inflammation in Type 2 asthma are emerging, we aimed to evaluate and meta-analyze the efficacy of monoclonal antibodies to reduce exacerbation rate.
De Feyter, Silke, Edris Mohamed, Ahmed, Joos, Guy, Lahousse, Lies, Maes, Tania   +4 more
core   +1 more source

Virtual screening for inhibitors of the human TSLP:TSLPR interaction [PDF]

, 2017
The pro-inflammatory cytokine thymic stromal lymphopoietin (TSLP) plays a pivotal role in the pathophysiology of various allergy disorders that are mediated by type 2 helper T cell (Th2) responses, such as asthma and atopic dermatitis.
AA Bogan, AC Braisted, AJ Souers, C Ghirelli, D Sun, DR Hall, G Neudert, G Pérez-Hernández, GM Gauvreau, HH Loeffler, J Corren, J Felix, J Yin, JM Wang, K Lindorff-Larsen, K Verstraete, K Verstraete, L Deng, LS Park, M Guillot-Delost, M Noti, M Piazza Di, MJ Abraham, NS Redhu, O Trott, P Buchwald, P Chames, RL Rich, S Demehri, S Doerr, S Ulrich, SD Levin, SF Ziegler, T Clackson   +33 more
core   +2 more sources

An Algorithm for the Diagnosis and Management of Severe Asthma in Children and Adolescents. [PDF]

Allergy
Allergy, Volume 81, Issue 1, Page 307-310, January 2026.
Hamelmann E, Schaub B, Lau S, Bacharier LB.   +3 more
europepmc   +2 more sources

Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma [PDF]

, 2017
The pro-inflammatory cytokine thymic stromal lymphopoietin (TSLP) is pivotal to the pathophysiology of widespread allergic diseases mediated by type 2 helper T cell (Th2) responses, including asthma and atopic dermatitis. The emergence of human TSLP as a
Beyaert, Rudi, Braun, Harald, Dansercoer, Ann, De Winter, Hans, Hammad, Hamida, Lambrecht, Bart, Lippens, Guy, Lopez, Juan, Pauwels, Kris, Peelman, Frank, Savvides, Savvas, Tavernier, Jan, Van Rompaey, Dries, Vandenberghe, Isabel, Verstraete, Kenneth   +14 more
core   +3 more sources

Tezepelumab in patients with allergic and eosinophilic asthma

Allergy, 2023
AbstractAsthma is a heterogeneous disease commonly driven by allergic and/or eosinophilic inflammation, both of which may be present in severe disease. Most approved biologics for severe asthma are indicated for specific phenotypes and target individual downstream type 2 components of the inflammatory cascade.
Marco Caminati, Roland Buhl, Jonathan Corren, Nicola A. Hanania, Harold Kim, Stephanie Korn, Marek Lommatzsch, Neil Martin, Andrea Matucci, Shuaib M. Nasser, Ian D. Pavord, Christian Domingo   +11 more
openaire   +4 more sources

We Have to Learn to Do Without Knowing Enough: Anti-Eosinophilic Treatments for Severe Asthma [PDF]

, 2018
Interleukin.5 (IL.5) is the main eosinophilic cytokine that promotes the differentiation, survival, and activation of eosinophils, which are the key inflammatory cells in severe eosinophilic asthma .Thus, it is no surprise that ...
4,, BEGHE', Bianca, Fabbri, Lm3, Papi, A1   +3 more
core   +1 more source

Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma

Biomedicines, 2021
Alarmins are innate cytokines, including thymic stromal lymphopoietin (TSLP), interleukin-33 (IL-33), and interleukin-25 (IL-25), which are mainly produced by airway epithelium and exert a prominent role in asthma pathobiology.
Corrado Pelaia, Giulia Pelaia, Federico Longhini, Claudia Crimi, Cecilia Calabrese, Luca Gallelli, Angela Sciacqua, Alessandro Vatrella   +7 more
doaj   +1 more source